For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
 Abbott LaboratoriesABT US · Health Care · USD Current price$102.98as of Sep 22, 2026 Summary
Analyst consensusStrong Buy 4Buy 18Hold 525 analysts 3-year price (USD)Factor profileMulti-factor score 67 / 100 Market data
Business descriptionAbbott Laboratories is a diversified health care products company operating across four segments: medical devices (48% of 2025 sales), diagnostics (20%), nutritional products (19%), and established pharmaceuticals (12%). The company holds leading market positions in diabetes care (Freestyle Libre CGM), cardiovascular devices, and noninvasive cancer screening following the Exact Sciences acquisition. Competitive moat
Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Aug 10, 2026
Current price: $102.98 · Sep 22, 2026· USD
CFRA Ratingbuy
TBI Multi Score67
Theme Exposure
Related Peers
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: ABTBusiness description
Abbott Laboratories is a diversified health care products company operating across four segments: medical devices (48% of 2025 sales), diagnostics (20%), nutritional products (19%), and established pharmaceuticals (12%). The company holds leading market positions in diabetes care (Freestyle Libre CGM), cardiovascular devices, and noninvasive cancer screening following the Exact Sciences acquisition.
Competitive moat
- Diversified health care portfolio spanning devices, diagnostics, nutrition, and generics insulates against single-market disruption.
- Strong brand equity in diabetes care (Freestyle Libre) with partnerships across five major insulin pump manufacturers.
- Leading position in noninvasive colorectal cancer screening via Cologuard / Cologuard Plus post-Exact Sciences acquisition.
- Sustained R&D investment ($2.94B in 2025) and a pipeline of 25+ innovative products expected over the next three years.
- Sturdy balance sheet with moderate leverage (20% debt/capital) and a 2.50% dividend yield with 54 years of consecutive payouts.
Recent developments
- Exact Sciences acquisition closed (March 2026): $21B equity value deal expands diagnostics TAM from $60B to $120B; Cologuard Plus provides runway in colorectal screening.
- Q2 2026 beat: Comparable sales growth of 4.8%, adjusted EPS of $1.31 exceeding guidance and consensus; full-year guidance raised.
- Strong product pipeline: Volt PFA system, TriClip enhancements, and Freestyle Libre 3 driving organic growth; 25 innovative products anticipated over three years.
- Nutrition recovery underway: Ongoing rebound in the nutrition business expected to support 2H 2026 momentum.
Investment risks / red flags
- Nutrition recovery execution: Dependent on continued market share recapture and sustained infant formula production stability following 2022 recall disruptions.
- China VBP exposure: Volume-Based Purchasing continues to pressure Diagnostics segment; could expand to other markets.
- GLP-1 medication impact: Growth in GLP-1 usage may affect procedure volumes and consumables demand.
- Regulatory timing: U.S. reimbursement expansion for CGM in Type 2 non-insulin patients remains an unpredictable catalyst.
Market Data
Source: mkts.io · Sep 22, 2026, 08:00 UTC
Key Metrics
P/E (TTM)33.33
P/E (Fwd)16.98
Dividend2.46%
Beta0.59
52W High$136.88
52W Low$81.97
Analyst Consensus
4
18
5
Strong Buy4Buy18Hold525 analysts
Consensus Target$120.26
+16.8% upside
Calendar Events
Next EarningsOct 14, 2026
Ex-DividendOct 15, 2026
Dividend DateNov 16, 2026
Financials
Revenue$46.58B
Rev Growth13.00%
Earnings Growth-47.50%
Gross Margin56.85%
Op Margin14.71%
Profit Margin11.65%
EBITDA$11.68B
ROA5.33%
ROE10.58%
Rev/Share$26.76
Total Cash$5.60B
Total Debt$32.72B
D/E Ratio63.21
Free Cash Flow$7.21B
Op Cash Flow$9.91B
Current Ratio1.38
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 1.42 | $12.99B |
| +1q | 1.64 | $13.54B |
| 0y | 5.52 | $50.20B |
| +1y | 6.07 | $54.53B |
Earnings
Quarterly EPS
3Q2025
Est: 1.301.30Beat
4Q2025
Est: 1.491.50Beat
1Q2026
Est: 1.151.15Beat
2Q2026
Est: 1.281.31Beat
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Sep 8, 2026 | TD Cowen | reit | Buy |
| Aug 25, 2026 | TD Cowen | main | Buy |
| Aug 21, 2026 | TD Cowen | main | Buy |
| Aug 14, 2026 | Citigroup | main | Buy |
| Aug 13, 2026 | Wolfe Research | up | Outperform |
| Jul 28, 2026 | UBS | main | Buy |